Intech Investment Management LLC Invests $754,000 in Guardant Health, Inc. (NASDAQ:GH)

Intech Investment Management LLC bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 32,848 shares of the company's stock, valued at approximately $754,000.

Several other institutional investors also recently modified their holdings of GH. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Guardant Health by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company's stock valued at $102,000 after buying an additional 796 shares in the last quarter. JNBA Financial Advisors acquired a new position in Guardant Health in the third quarter valued at about $26,000. Ashton Thomas Securities LLC bought a new stake in shares of Guardant Health in the third quarter worth about $34,000. Quarry LP bought a new stake in shares of Guardant Health in the second quarter worth about $44,000. Finally, Green Alpha Advisors LLC raised its position in shares of Guardant Health by 23.6% during the third quarter. Green Alpha Advisors LLC now owns 8,782 shares of the company's stock worth $201,000 after purchasing an additional 1,674 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Guardant Health news, Director Meghan V. Joyce sold 2,896 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the transaction, the director now directly owns 7,648 shares of the company's stock, valued at $228,675.20. This represents a 27.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is owned by insiders.

Guardant Health Stock Performance

Shares of GH traded up $0.51 during midday trading on Friday, reaching $35.61. The stock had a trading volume of 815,237 shares, compared to its average volume of 2,067,785. The firm has a market cap of $4.40 billion, a PE ratio of -8.40 and a beta of 1.11. The firm has a 50 day simple moving average of $25.21 and a 200-day simple moving average of $27.34. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $37.04. The company has a current ratio of 6.22, a quick ratio of 5.85 and a debt-to-equity ratio of 16.70.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.33). The business had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company's revenue for the quarter was up 33.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.73) EPS. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -3.38 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on GH shares. The Goldman Sachs Group increased their target price on Guardant Health from $32.00 to $36.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Leerink Partners lowered their price objective on shares of Guardant Health from $60.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, October 17th. Citigroup boosted their price objective on shares of Guardant Health from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Thursday, August 8th. Piper Sandler upped their target price on shares of Guardant Health from $30.00 to $34.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 13th. Finally, Sanford C. Bernstein dropped their price target on Guardant Health from $40.00 to $35.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $40.60.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.